In the past week, HALO stock has gone down by -2.04%, with a monthly decline of -12.88% and a quarterly plunge of -8.31%. The volatility ratio for the week is 2.83%, and the volatility levels for the last 30 days are 7.90% for Halozyme Therapeutics Inc The simple moving average for the past 20 days is -5.34% for HALO’s stock, with a -5.41% simple moving average for the past 200 days.
Is It Worth Investing in Halozyme Therapeutics Inc (NASDAQ: HALO) Right Now?
Halozyme Therapeutics Inc (NASDAQ: HALO) has a higher price-to-earnings ratio of 14.14x compared to its average ratio, The 36-month beta value for HALO is at 1.19. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for HALO is 121.86M, and currently, shorts hold a 8.77% of that float. The average trading volume for HALO on June 04, 2025 was 2.18M shares.
HALO) stock’s latest price update
Halozyme Therapeutics Inc (NASDAQ: HALO)’s stock price has plunge by -4.19relation to previous closing price of 55.64. Nevertheless, the company has seen a -2.04% plunge in its stock price over the last five trading sessions. zacks.com reported 2025-06-03 that STRL, BJ, MOH, and HALO shine with strong interest coverage ratios, signaling solid fundamentals for June 2025.
Analysts’ Opinion of HALO
Many brokerage firms have already submitted their reports for HALO stocks, with Morgan Stanley repeating the rating for HALO by listing it as a “Equal-Weight.” The predicted price for HALO in the upcoming period, according to Morgan Stanley is $62 based on the research report published on May 14, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see HALO reach a price target of $47. The rating they have provided for HALO stocks is “Underperform” according to the report published on May 13th, 2025.
Wells Fargo gave a rating of “Equal Weight” to HALO, setting the target price at $62 in the report published on October 07th of the previous year.
HALO Trading at -9.70% from the 50-Day Moving Average
After a stumble in the market that brought HALO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.39% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HALO starting from Henderson Jeffrey William, who sale 4,497 shares at the price of $60.37 back on Apr 28 ’25. After this action, Henderson Jeffrey William now owns 28,611 shares of Halozyme Therapeutics Inc, valued at $271,467 using the latest closing price.
Henderson Jeffrey William, the Director of Halozyme Therapeutics Inc, sale 503 shares at $64.05 during a trade that took place back on Apr 01 ’25, which means that Henderson Jeffrey William is holding 33,108 shares at $32,217 based on the most recent closing price.
Stock Fundamentals for HALO
Current profitability levels for the company are sitting at:
- 0.55 for the present operating margin
- 0.82 for the gross margin
The net margin for Halozyme Therapeutics Inc stands at 0.45. The total capital return value is set at 0.29. Equity return is now at value 147.06, with 24.04 for asset returns.
Based on Halozyme Therapeutics Inc (HALO), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.33. The debt to equity ratio resting at 3.13. The interest coverage ratio of the stock is 32.99.
Currently, EBITDA for the company is 656.54 million with net debt to EBITDA at 1.9. When we switch over and look at the enterprise to sales, we see a ratio of 7.29. The receivables turnover for the company is 3.56for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.39.
Conclusion
In conclusion, Halozyme Therapeutics Inc (HALO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
